These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 7791695)

  • 21. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
    Shaaltiel Y; Bartfeld D; Hashmueli S; Baum G; Brill-Almon E; Galili G; Dym O; Boldin-Adamsky SA; Silman I; Sussman JL; Futerman AH; Aviezer D
    Plant Biotechnol J; 2007 Sep; 5(5):579-90. PubMed ID: 17524049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked clinical and histologic improvement in a patient with type-1 Gaucher's disease following long-term glucocerebroside substitution. A case report and review of current diagnosis and management.
    Heukamp LC; Schröder DW; Plassmann D; Homann J; Büttner R
    Pathol Res Pract; 2003; 199(3):159-63. PubMed ID: 12812317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy.
    Burrow TA; Cohen MB; Bokulic R; Deutsch G; Choudhary A; Falcone RA; Grabowski GA
    J Pediatr; 2007 Feb; 150(2):202-6. PubMed ID: 17236903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Gaucher's disease. Report of 4 cases].
    Adarraga Cansino MD; Fernández de la Puebla R; Jiménez Perepérez JA; Pocoví Mieras M; Zambrana García JL; Pérez Jiménez F
    Rev Clin Esp; 2002 Dec; 202(12):635-7. PubMed ID: 12459090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R; Goa KL
    Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gaucher's disease: therapy by intravenous infusions of modified glucocerebrosidase.
    Beck M; Valadares ER; Lotz J
    Clin Investig; 1993 Jan; 71(1):78. PubMed ID: 8453266
    [No Abstract]   [Full Text] [Related]  

  • 28. Enzyme replacement therapy in Gaucher's and Fabry's disease.
    Pentchev PG
    Ann Clin Lab Sci; 1977; 7(3):251-3. PubMed ID: 404951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme-replacement therapy for Gaucher's disease.
    N Engl J Med; 1991 Dec; 325(25):1809-11. PubMed ID: 1944489
    [No Abstract]   [Full Text] [Related]  

  • 30. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
    Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocerebrosidase for treatment of Gaucher's disease: first German long-term results.
    Niederau C; Holderer A; Heintges T; Strohmeyer G
    J Hepatol; 1994 Oct; 21(4):610-7. PubMed ID: 7814809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
    J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
    Pérez-Calvo J; Giraldo P; Pastores GM; Fernández-Galán M; Martín-Nuñez G; Pocoví M
    J Postgrad Med; 2003; 49(2):127-31. PubMed ID: 12867687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gaucher's disease in Lithuania: its diagnosis and treatment.
    Kleinotienė G; Tylki-Szymanska A; Czartoryska B
    Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Principles of diagnosis and the clinical course of 8 cases of Gaucher's disease (beta-glucocerebrosidase deficiency)].
    Tylki-Szymańska A; Maciejko D; Rujner J; Goryluk B; Pronicka E
    Pediatr Pol; 1987 Jan; 62(1):9-18. PubMed ID: 3615053
    [No Abstract]   [Full Text] [Related]  

  • 37. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ
    Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurological features in Gaucher's disease during enzyme replacement therapy.
    Ono H; Fujiwara M; Ito K; Ueda H; Mizoguchi N; Sakura N
    Acta Paediatr; 2001 Feb; 90(2):229-31. PubMed ID: 11236058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.
    Vitner EB; Farfel-Becker T; Eilam R; Biton I; Futerman AH
    Brain; 2012 Jun; 135(Pt 6):1724-35. PubMed ID: 22566609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Response criteria for enzyme substitution in Gaucher disease].
    Berthold F; Sieverts H; Benz-Bohm G; Landwehr P; Harzer K
    Monatsschr Kinderheilkd; 1992 Oct; 140(10):740-4. PubMed ID: 1331780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.